Has HCA Healthcare Stock Quietly Become a Value Opportunity?
HCA Healthcare (HCA) stock is at an interesting point right now. It is trading cheap, and if you bet on it, you are betting on a company that’s growing reasonably, is sustaining good cash flow and margin, and is relatively cheaply valued. But is that enough?
Why Bet On HCA Now?
HCA is leveraging its dominant scale and network density in high-growth urban markets to capture a greater share of profitable outpatient and high-acuity services. This strategy, combined with superior operational efficiencies and significant capital returns, creates a durable, compounding investment vehicle capable of navigating near-term reimbursement pressures.
- HCA holds the #1 or #2 inpatient market share in approximately 80% of its markets.
- The company is actively targeting a market share increase from 27% to 29% by 2030.
- Outpatient services, which are growing faster than inpatient services, now account for approximately 38.4% of total patient revenues.
- Management has authorized a new $10 billion share repurchase program, signaling confidence in future cash flow generation.
How Do The Fundamentals Look?
- Revenue Growth: 7.1% LTM and 7.9% last 3 year average.
- Operating Margin: Nearly 15.2% 3-year average operating margin.
- No Margin Shock: HCA Healthcare has improved in the last 12 months.
- Modest Valuation: Despite these fundamentals, HCA stock trades at a PE multiple of 16.2
Below is a quick comparison of HCA fundamentals with S&P medians.
| HCA | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Health Care Facilities | – |
| PE Ratio | 16.2 | 23.6 |
|
|
||
| LTM* Revenue Growth | 7.1% | 6.6% |
| 3Y Average Annual Revenue Growth | 7.9% | 5.5% |
| LTM Operating Margin Change | 0.9% | 0.2% |
|
|
||
| LTM* Operating Margin | 15.8% | 18.7% |
| 3Y Average Operating Margin | 15.2% | 18.2% |
| LTM* Free Cash Flow Margin | 10.2% | 14.3% |
*LTM: Last Twelve Months
The Bear View & The Current Investment Debate
The current investment debate on HCAis centered around: Can HCA’s scale and efficiency offset a direct $600M-$900M EBITDA headwind from ACA policy changes, or will payer mix deterioration finally disrupt its compounding growth story?
The prevailing sentiment is bullish. Known headwinds are priced. Management’s consistent beat-and-raise history and massive buyback signal confidence. The market is rewarding HCA as a resilient compounder, not just a hospital subject to policy whims.
| Bull View | Bear View |
|---|---|
| HCA’s ‘resiliency program’ and operational excellence will absorb the guided ACA headwind, allowing for continued 2-3% patient volume growth and margin stability, proving its ‘all-weather’ thesis. | The payer mix shift from the ACA changes will be worse than guided, causing the EBITDA impact to exceed $900M and leading to a 2026 earnings miss. |
You can evaluate more on which view to bet on by visiting HCA Investment Highlights & Full Analysis
HCA Is Just One of Several Such Stocks
Not ready to act on HCA? Consider these alternatives:
We chose these stocks using the following criteria:
- Greater than $2 Bil in market cap
- Meaningfully below 1Y high
- Current P/S < last few year average
- Strong operating margin
- P/E ratio below S&P 500 median
A portfolio of stocks with the criteria above would have performed has follows since 12/31/2016:
- Average 6-month and 12-month forward returns of 12.7% and 25.8% respectively
- Win rate (percentage of picks returning positive) of > 70% for both 6-month and 12-month periods
- Strategy consistent across market cycles
Portfolios Over Individual Stock Picks
Single stocks swing wildly but staying invested matters. A well built portfolio helps you stay invested, captures upside and softens the blows from individual stocks.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.